Yousry C, Ahmed I, M Amin M, El Gazayerly O
Pharmaceutics. 2019; 11(6).
PMID: 31159447
PMC: 6630550.
DOI: 10.3390/pharmaceutics11060257.
Salah S, Mahmoud A, Kamel A
Drug Deliv. 2017; 24(1):846-856.
PMID: 28535740
PMC: 8240986.
DOI: 10.1080/10717544.2017.1326539.
Devarakonda K, Vandenbossche J, Richarz U
Springerplus. 2013; 2:625.
PMID: 24349945
PMC: 3863398.
DOI: 10.1186/2193-1801-2-625.
Zerbe H, Luckow V, Cawello W, Cordes G
Pharm Res. 2013; 2(1):30-6.
PMID: 24272511
DOI: 10.1023/A:1016314005874.
Endrenyi L, Tothfalusi L
AAPS J. 2012; 14(4):813-9.
PMID: 22910857
PMC: 3475860.
DOI: 10.1208/s12248-012-9396-8.
Preparation and in-vivo pharmacokinetic study of a novel extended release compression coated tablets of fenoterol hydrobromide.
Elshafeey A, Sami E
AAPS PharmSciTech. 2008; 9(3):1016-24.
PMID: 18770048
PMC: 2977029.
DOI: 10.1208/s12249-008-9135-8.
In vitro and in vivo evaluation of single-unit commercial conventional tablet and sustained-release capsules compared with multiple-unit polystyrene microparticle dosage forms of Ibuprofen.
Tamilvanan S, Sa B
AAPS PharmSciTech. 2006; 7(3):72.
PMID: 17025252
PMC: 2750514.
DOI: 10.1208/pt070372.
The pharmacokinetic basis of optimal antibiotic dosage.
von Hattingberg H, Brockmeier D
Infection. 1980; Suppl 1:21-4.
PMID: 7399709
DOI: 10.1007/BF01644930.
A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tablet.
Aellig W, Narjes H, Nuesch E, Oertle R, Devos J, Pacha W
Eur J Clin Pharmacol. 1981; 20(3):179-83.
PMID: 7286035
DOI: 10.1007/BF00544595.
Pharmacokinetic comparison of pindolol 30 mg retard and 15 mg normal tablets.
Aellig W, Nuesch E, Pacha W
Eur J Clin Pharmacol. 1982; 21(6):451-5.
PMID: 7075650
DOI: 10.1007/BF00542037.
Oral controlled release dosage forms. A review.
de Haan P, Lerk C
Pharm Weekbl Sci. 1984; 6(2):57-67.
PMID: 6374610
DOI: 10.1007/BF01953956.
Absorption kinetics of dihydroergotoxine following oral administration to man.
Woodcock B, Rietbrock N, Loh W, Habedank W
Br J Clin Pharmacol. 1985; 20(6):603-9.
PMID: 4091992
PMC: 1400840.
DOI: 10.1111/j.1365-2125.1985.tb05118.x.
Pharmacokinetics of sustained-release verapamil after a single administration and at steady state.
Mattila J, Mantyla R, Taskinen J, Mannisto P
Eur J Drug Metab Pharmacokinet. 1985; 10(2):133-8.
PMID: 3840089
DOI: 10.1007/BF03189707.
Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers.
Gordin A, POHTO P, Sundberg S, Nykanen S, Haataja H, Mannisto P
Eur J Clin Pharmacol. 1986; 31(4):423-6.
PMID: 3816921
DOI: 10.1007/BF00613518.
Bioavailability of indomethacin from a modified release system containing indomethacin as the lysine salt.
Marzo A, Reiner A, ARRIGONI MARTELLI E, Conte U, Colombo P, La Manna A
Eur J Clin Pharmacol. 1987; 32(1):85-7.
PMID: 3108010
DOI: 10.1007/BF00609963.
Pharmacokinetic characterization of controlled-release formulations.
Steinijans V
Eur J Drug Metab Pharmacokinet. 1990; 15(2):173-81.
PMID: 2200687
DOI: 10.1007/BF03190201.
Pharmacokinetics and pharmacodynamics of conventional and controlled-release formulations of metipranolol in man.
Lapka R, Sechser T, REJHOLEC V, Peterkova M, Votavova M
Eur J Clin Pharmacol. 1990; 38(3):243-7.
PMID: 1971217
DOI: 10.1007/BF00315024.
Pharmacokinetics and pharmacodynamics of a new transdermal delivery system for bopindolol.
Drewe J, Meier R, Timonen U, Thumshirn M, MUNZER J, Kissel T
Br J Clin Pharmacol. 1991; 31(6):671-6.
PMID: 1678271
PMC: 1368578.
DOI: 10.1111/j.1365-2125.1991.tb05591.x.
Enhancement of the oral absorption of cyclosporin in man.
Drewe J, Meier R, Vonderscher J, Kiss D, Posanski U, Kissel T
Br J Clin Pharmacol. 1992; 34(1):60-4.
PMID: 1633069
PMC: 1381376.
DOI: 10.1111/j.1365-2125.1992.tb04108.x.
Controversies in bioequivalence studies.
Steinijans V, Hauschke D, Jonkman J
Clin Pharmacokinet. 1992; 22(4):247-53.
PMID: 1606785
DOI: 10.2165/00003088-199222040-00001.
